Navigation Links


Eprodisate in Medical News

Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational pr...

Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis

ECUBLENS, Switzerland, Dec. 14 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medi...

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review

ECUBLENS, Switzerland, Dec. 6 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company has received an acknowledgement from the United States Food and Drug Administration (FDA) tha...

BELLUS Health reports results for first quarter of fiscal 2009

...revenue (non-monetary liability) to accrued liability (monetary liability) following the recovery by the Company of ownership rights in and control of eprodisate (KIACTA(TM)). Other income amounted to $529,000 for the current quarter, compared to $278,000 for the same quarter the previous year. Other incom...

BELLUS Health reports results for the fourth quarter of 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ision to continue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food...

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

...arily due to funds used in operating activities. eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis With respect to eprodisate (KIACTA(TM)), the Company submitted a proposed pro...II trial, should be sufficient to gain approval of eprodisate (KIACTA(TM)) for the treatment of AA Amyloidosis,....

BELLUS Health provides update on activities

...lic syndrome and Alzheimer's disease. The Company expects to file the Investigational New Drug application for the second Phase III clinical trial for eprodisate (KIACTA(TM)) for the treatment of Amyloid A amyloidosis in the fourth quarter of 2008. With respect to this second Phase III KIACTA(TM) clinical tri...

BELLUS HEALTH reports results for first quarter of fiscal 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ecision to pursue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Fo...

At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)

...also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and ...ly announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administratio...

Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives

...n July 2007 for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i... the marketing authorization application (MAA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i...ts of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns...
Eprodisate in Medical Technology

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. , announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognize...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

...t Neurochem Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by th...
Other TagsLavageLesion
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 1Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 2In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 1In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 2Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 1Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 2Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 3
Other Contentspneumococcalpneumococcalpneumoconiosiscariniipodiatrypoliomyelitisnodosapolyarteritis